Key clinical point: Intraoperative cell salvage (ICS) is an effective and safe method for blood loss recovery in patients with a high risk for postpartum hemorrhage (PPH) during cesarean section.

Major finding: Patients who underwent ICS vs received allogeneic red blood cell (RBC) transfusion had significantly higher blood cell count, hemoglobin levels, hematocrit, and fibrinogen levels, and shorter prothrombin time, thrombin time, and activated partial thromboplastin time (all P < .05). ICS treatment did not cause any adverse events.

Study details: This prospective randomized controlled study included 130 patients with a high risk for PPH who underwent elective or emergency cesarean section and were randomly assigned (1:1) to undergo ICS (n = 65) or receive allogeneic RBC transfusion (control; n = 65) if the hemoglobin level was <80 g/L during surgery.

Disclosures: This study was sponsored by the Beijing Science and Technology Commission Research Fund, China. The authors declared no conflicts of interest.

Source: Lei B et al. Intraoperative cell salvage as an effective intervention for postpartum hemorrhage—Evidence from a prospective randomized controlled trial. Front Immunol. 2022;13:953334 (Oct 10). Doi: 10.3389/fimmu.2022.953334

Key clinical point: Intraoperative cell salvage (ICS) is an effective and safe method for blood loss recovery in patients with a high risk for postpartum hemorrhage (PPH) during cesarean section.

Major finding: Patients who underwent ICS vs received allogeneic red blood cell (RBC) transfusion had significantly higher blood cell count, hemoglobin levels, hematocrit, and fibrinogen levels, and shorter prothrombin time, thrombin time, and activated partial thromboplastin time (all P < .05). ICS treatment did not cause any adverse events.

Study details: This prospective randomized controlled study included 130 patients with a high risk for PPH who underwent elective or emergency cesarean section and were randomly assigned (1:1) to undergo ICS (n = 65) or receive allogeneic RBC transfusion (control; n = 65) if the hemoglobin level was <80 g/L during surgery.

Disclosures: This study was sponsored by the Beijing Science and Technology Commission Research Fund, China. The authors declared no conflicts of interest.

Source: Lei B et al. Intraoperative cell salvage as an effective intervention for postpartum hemorrhage—Evidence from a prospective randomized controlled trial. Front Immunol. 2022;13:953334 (Oct 10). Doi: 10.3389/fimmu.2022.953334

Key clinical point: Intraoperative cell salvage (ICS) is an effective and safe method for blood loss recovery in patients with a high risk for postpartum hemorrhage (PPH) during cesarean section.

Major finding: Patients who underwent ICS vs received allogeneic red blood cell (RBC) transfusion had significantly higher blood cell count, hemoglobin levels, hematocrit, and fibrinogen levels, and shorter prothrombin time, thrombin time, and activated partial thromboplastin time (all P < .05). ICS treatment did not cause any adverse events.

Study details: This prospective randomized controlled study included 130 patients with a high risk for PPH who underwent elective or emergency cesarean section and were randomly assigned (1:1) to undergo ICS (n = 65) or receive allogeneic RBC transfusion (control; n = 65) if the hemoglobin level was <80 g/L during surgery.

Disclosures: This study was sponsored by the Beijing Science and Technology Commission Research Fund, China. The authors declared no conflicts of interest.

Source: Lei B et al. Intraoperative cell salvage as an effective intervention for postpartum hemorrhage—Evidence from a prospective randomized controlled trial. Front Immunol. 2022;13:953334 (Oct 10). Doi: 10.3389/fimmu.2022.953334

Key clinical point: A dose of 1 g intravenous tranexamic acid vs placebo significantly inhibited postpartum hemorrhage-induced hyperfibrinolysis during cesarean delivery.

Major finding: A dose of 1 g tranexamic acid vs placebo significantly inhibited postpartum hemorrhage-induced hyperfibrinolysis as evidenced by smaller mean increases in D-dimer levels at 120 minutes (38% vs 93%; P = .003) and plasmin-antiplasmin levels at 30 minutes (−2% vs 56%; P = .009) after the initiation of infusion but with more frequent nonserious adverse events, such as nausea and vomiting, whereas 0.5 g tranexamic acid did not lead to significant hyperfibrinolysis inhibition.

Study details: The data come from the phase 4 TRACES trial including 151 women who experienced postpartum hemorrhage during cesarean delivery and were randomly assigned to receive tranexamic acid (0.5 or 1 g) or placebo.

Disclosures: This study was supported by the French Ministry of Health and the French National Drug Safety Agency. The authors declared no conflicts of interest.

Source: Ducloy-Bouthors AS et al for the TRACES working group. Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study. Br J Anaesth. 2022;129(6):937-945 (Oct 12). Doi: 10.1016/j.bja.2022.08.033

Key clinical point: A dose of 1 g intravenous tranexamic acid vs placebo significantly inhibited postpartum hemorrhage-induced hyperfibrinolysis during cesarean delivery.

Major finding: A dose of 1 g tranexamic acid vs placebo significantly inhibited postpartum hemorrhage-induced hyperfibrinolysis as evidenced by smaller mean increases in D-dimer levels at 120 minutes (38% vs 93%; P = .003) and plasmin-antiplasmin levels at 30 minutes (−2% vs 56%; P = .009) after the initiation of infusion but with more frequent nonserious adverse events, such as nausea and vomiting, whereas 0.5 g tranexamic acid did not lead to significant hyperfibrinolysis inhibition.

Study details: The data come from the phase 4 TRACES trial including 151 women who experienced postpartum hemorrhage during cesarean delivery and were randomly assigned to receive tranexamic acid (0.5 or 1 g) or placebo.

Disclosures: This study was supported by the French Ministry of Health and the French National Drug Safety Agency. The authors declared no conflicts of interest.

Source: Ducloy-Bouthors AS et al for the TRACES working group. Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study. Br J Anaesth. 2022;129(6):937-945 (Oct 12). Doi: 10.1016/j.bja.2022.08.033

Key clinical point: A dose of 1 g intravenous tranexamic acid vs placebo significantly inhibited postpartum hemorrhage-induced hyperfibrinolysis during cesarean delivery.

Major finding: A dose of 1 g tranexamic acid vs placebo significantly inhibited postpartum hemorrhage-induced hyperfibrinolysis as evidenced by smaller mean increases in D-dimer levels at 120 minutes (38% vs 93%; P = .003) and plasmin-antiplasmin levels at 30 minutes (−2% vs 56%; P = .009) after the initiation of infusion but with more frequent nonserious adverse events, such as nausea and vomiting, whereas 0.5 g tranexamic acid did not lead to significant hyperfibrinolysis inhibition.

Study details: The data come from the phase 4 TRACES trial including 151 women who experienced postpartum hemorrhage during cesarean delivery and were randomly assigned to receive tranexamic acid (0.5 or 1 g) or placebo.

Disclosures: This study was supported by the French Ministry of Health and the French National Drug Safety Agency. The authors declared no conflicts of interest.

Source: Ducloy-Bouthors AS et al for the TRACES working group. Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study. Br J Anaesth. 2022;129(6):937-945 (Oct 12). Doi: 10.1016/j.bja.2022.08.033

Key clinical point: Low molecular weight heparin (LMWH), vitamin D supplementation, exercise, calcium supplementation, and aspirin reduce the risk for preeclampsia.

Major finding: LMWH (risk ratio [RR] 0.60; 95% CI 0.42-0.87), vitamin D supplementation (RR 0.65; 95% CI 0.45-0.95), exercise (RR 0.68; 95% CI 0.50-0.92), calcium supplementation (RR 0.71; 95% CI 0.62-0.82), and aspirin (RR 0.79; 95% CI 0.72-0.86) were the prophylactic strategies identified to significantly reduce the risk for preeclampsia.

Study details: Findings are from a network meta-analysis of 130 randomized controlled trials that involved 112,916 pregnant women at risk of developing preeclampsia, with preeclampsia being reported in 114 studies including 95,500 women.

Disclosures: This study was supported by the Shuangqing Talent Program Project of Guangdong Provincial People's Hospital, China, among others. The authors declared no conflicts of interest.

Source: Liu YH et al. Prophylactic strategies for preventing pre-eclampsia: A network meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2022 (Oct 22). Doi: 10.1016/j.ajog.2022.10.014

Key clinical point: Low molecular weight heparin (LMWH), vitamin D supplementation, exercise, calcium supplementation, and aspirin reduce the risk for preeclampsia.

Major finding: LMWH (risk ratio [RR] 0.60; 95% CI 0.42-0.87), vitamin D supplementation (RR 0.65; 95% CI 0.45-0.95), exercise (RR 0.68; 95% CI 0.50-0.92), calcium supplementation (RR 0.71; 95% CI 0.62-0.82), and aspirin (RR 0.79; 95% CI 0.72-0.86) were the prophylactic strategies identified to significantly reduce the risk for preeclampsia.

Study details: Findings are from a network meta-analysis of 130 randomized controlled trials that involved 112,916 pregnant women at risk of developing preeclampsia, with preeclampsia being reported in 114 studies including 95,500 women.

Disclosures: This study was supported by the Shuangqing Talent Program Project of Guangdong Provincial People's Hospital, China, among others. The authors declared no conflicts of interest.

Source: Liu YH et al. Prophylactic strategies for preventing pre-eclampsia: A network meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2022 (Oct 22). Doi: 10.1016/j.ajog.2022.10.014

Key clinical point: Low molecular weight heparin (LMWH), vitamin D supplementation, exercise, calcium supplementation, and aspirin reduce the risk for preeclampsia.

Major finding: LMWH (risk ratio [RR] 0.60; 95% CI 0.42-0.87), vitamin D supplementation (RR 0.65; 95% CI 0.45-0.95), exercise (RR 0.68; 95% CI 0.50-0.92), calcium supplementation (RR 0.71; 95% CI 0.62-0.82), and aspirin (RR 0.79; 95% CI 0.72-0.86) were the prophylactic strategies identified to significantly reduce the risk for preeclampsia.

Study details: Findings are from a network meta-analysis of 130 randomized controlled trials that involved 112,916 pregnant women at risk of developing preeclampsia, with preeclampsia being reported in 114 studies including 95,500 women.

Disclosures: This study was supported by the Shuangqing Talent Program Project of Guangdong Provincial People's Hospital, China, among others. The authors declared no conflicts of interest.

Source: Liu YH et al. Prophylactic strategies for preventing pre-eclampsia: A network meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2022 (Oct 22). Doi: 10.1016/j.ajog.2022.10.014

Key clinical point: Compared with women who conceive naturally, those who conceive through assisted reproductive technology (ART) have a higher risk for cardiovascular complications, including preeclampsia/eclampsia, heart failure, and cardiac arrhythmias, during delivery admissions.

Major finding: Women who conceived through ART vs naturally had a higher risk for preeclampsia/eclampsia (adjusted odds ratio [aOR] 1.48; P < .01), heart failure (aOR 1.94; P < .01), and cardiac arrhythmias (aOR 1.39; P < .01).

Study details: This real-world population study analyzed the data of women hospitalized for deliveries (weighted n = 45,867,086), of which 108,542 had conceived through ART.

Disclosures: This study did not receive any specific funding. Some authors declared advisory board participation or consultancy for various organizations.

Source: Zahid S et al. Cardiovascular complications during delivery admissions associated with assisted reproductive technology (from a National Inpatient Sample analysis 2008 to 2019). Am J Cardiol. 2022 (Oct 23). Doi: 10.1016/j.amjcard.2022.08.037

Key clinical point: Compared with women who conceive naturally, those who conceive through assisted reproductive technology (ART) have a higher risk for cardiovascular complications, including preeclampsia/eclampsia, heart failure, and cardiac arrhythmias, during delivery admissions.

Major finding: Women who conceived through ART vs naturally had a higher risk for preeclampsia/eclampsia (adjusted odds ratio [aOR] 1.48; P < .01), heart failure (aOR 1.94; P < .01), and cardiac arrhythmias (aOR 1.39; P < .01).

Study details: This real-world population study analyzed the data of women hospitalized for deliveries (weighted n = 45,867,086), of which 108,542 had conceived through ART.

Disclosures: This study did not receive any specific funding. Some authors declared advisory board participation or consultancy for various organizations.

Source: Zahid S et al. Cardiovascular complications during delivery admissions associated with assisted reproductive technology (from a National Inpatient Sample analysis 2008 to 2019). Am J Cardiol. 2022 (Oct 23). Doi: 10.1016/j.amjcard.2022.08.037

Key clinical point: Compared with women who conceive naturally, those who conceive through assisted reproductive technology (ART) have a higher risk for cardiovascular complications, including preeclampsia/eclampsia, heart failure, and cardiac arrhythmias, during delivery admissions.

Major finding: Women who conceived through ART vs naturally had a higher risk for preeclampsia/eclampsia (adjusted odds ratio [aOR] 1.48; P < .01), heart failure (aOR 1.94; P < .01), and cardiac arrhythmias (aOR 1.39; P < .01).

Study details: This real-world population study analyzed the data of women hospitalized for deliveries (weighted n = 45,867,086), of which 108,542 had conceived through ART.

Disclosures: This study did not receive any specific funding. Some authors declared advisory board participation or consultancy for various organizations.

Source: Zahid S et al. Cardiovascular complications during delivery admissions associated with assisted reproductive technology (from a National Inpatient Sample analysis 2008 to 2019). Am J Cardiol. 2022 (Oct 23). Doi: 10.1016/j.amjcard.2022.08.037

Key clinical point: Crofelemer failed to reduce the incidence rate of any grade chemotherapy-induced diarrhea (CID) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who received trastuzumab, pertuzumab, and a taxane.

Major finding: During cycle 2 of chemotherapy, a similar proportion of patients reported any grade diarrhea for ≥2 consecutive days (P = .742), but the rate of grade ≥2 diarrhea was significantly reduced (8.0% vs 39.1%; P = .0196) in the crofelemer vs no scheduled prophylactic medication treatment group.

Study details: Findings are from the phase 2 HALT-D study including 51 patients with HER2+ BC who were randomly assigned to receive 125 mg crofelemer or no scheduled prophylactic medication during cycles 1 and 2 of chemotherapy/HER2-targeted therapy.

Disclosures: This study was supported by Genentech, Inc., and other sources. The authors declared serving as consultants, advisors or receiving honoraria, research funding, consulting fees, speaking fees, or travel support from several sources, including Genentech.

Source: Pohlmann PR et al. HALT-D: A randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast Cancer Res Treat. 2022;196(3):571-581 (Oct 25). Doi: 10.1007/s10549-022-06743-9

Key clinical point: Crofelemer failed to reduce the incidence rate of any grade chemotherapy-induced diarrhea (CID) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who received trastuzumab, pertuzumab, and a taxane.

Major finding: During cycle 2 of chemotherapy, a similar proportion of patients reported any grade diarrhea for ≥2 consecutive days (P = .742), but the rate of grade ≥2 diarrhea was significantly reduced (8.0% vs 39.1%; P = .0196) in the crofelemer vs no scheduled prophylactic medication treatment group.

Study details: Findings are from the phase 2 HALT-D study including 51 patients with HER2+ BC who were randomly assigned to receive 125 mg crofelemer or no scheduled prophylactic medication during cycles 1 and 2 of chemotherapy/HER2-targeted therapy.

Disclosures: This study was supported by Genentech, Inc., and other sources. The authors declared serving as consultants, advisors or receiving honoraria, research funding, consulting fees, speaking fees, or travel support from several sources, including Genentech.

Source: Pohlmann PR et al. HALT-D: A randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast Cancer Res Treat. 2022;196(3):571-581 (Oct 25). Doi: 10.1007/s10549-022-06743-9

Key clinical point: Crofelemer failed to reduce the incidence rate of any grade chemotherapy-induced diarrhea (CID) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who received trastuzumab, pertuzumab, and a taxane.

Major finding: During cycle 2 of chemotherapy, a similar proportion of patients reported any grade diarrhea for ≥2 consecutive days (P = .742), but the rate of grade ≥2 diarrhea was significantly reduced (8.0% vs 39.1%; P = .0196) in the crofelemer vs no scheduled prophylactic medication treatment group.

Study details: Findings are from the phase 2 HALT-D study including 51 patients with HER2+ BC who were randomly assigned to receive 125 mg crofelemer or no scheduled prophylactic medication during cycles 1 and 2 of chemotherapy/HER2-targeted therapy.

Disclosures: This study was supported by Genentech, Inc., and other sources. The authors declared serving as consultants, advisors or receiving honoraria, research funding, consulting fees, speaking fees, or travel support from several sources, including Genentech.

Source: Pohlmann PR et al. HALT-D: A randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast Cancer Res Treat. 2022;196(3):571-581 (Oct 25). Doi: 10.1007/s10549-022-06743-9

Key clinical point: In elderly patients who received endocrine monotherapy for breast cancer (BC), the risk of dying due to other conditions was more than twice the risk for eventually requiring invasive local treatment.

Major finding: Within 5 years, 28% of patients required invasive local treatment (surgery or radiotherapy) and the overall mortality risk (overall survival 42%) was >2 times higher than the risk of undergoing invasive local treatment.

Study details: Findings are from a retrospective cohort study including 91 elderly (≥70 years) female patients with estrogen receptor-positive (ER+) BC who received endocrine monotherapy as a definitive treatment.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Gooijer SA et al. Long-term outcome of sustained endocrine monotherapy for elderly breast cancer patients. Ann Surg Oncol. 2022 (Nov 3). Doi: 10.1245/s10434-022-12662-2

Key clinical point: In elderly patients who received endocrine monotherapy for breast cancer (BC), the risk of dying due to other conditions was more than twice the risk for eventually requiring invasive local treatment.

Major finding: Within 5 years, 28% of patients required invasive local treatment (surgery or radiotherapy) and the overall mortality risk (overall survival 42%) was >2 times higher than the risk of undergoing invasive local treatment.

Study details: Findings are from a retrospective cohort study including 91 elderly (≥70 years) female patients with estrogen receptor-positive (ER+) BC who received endocrine monotherapy as a definitive treatment.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Gooijer SA et al. Long-term outcome of sustained endocrine monotherapy for elderly breast cancer patients. Ann Surg Oncol. 2022 (Nov 3). Doi: 10.1245/s10434-022-12662-2

Key clinical point: In elderly patients who received endocrine monotherapy for breast cancer (BC), the risk of dying due to other conditions was more than twice the risk for eventually requiring invasive local treatment.

Major finding: Within 5 years, 28% of patients required invasive local treatment (surgery or radiotherapy) and the overall mortality risk (overall survival 42%) was >2 times higher than the risk of undergoing invasive local treatment.

Study details: Findings are from a retrospective cohort study including 91 elderly (≥70 years) female patients with estrogen receptor-positive (ER+) BC who received endocrine monotherapy as a definitive treatment.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Gooijer SA et al. Long-term outcome of sustained endocrine monotherapy for elderly breast cancer patients. Ann Surg Oncol. 2022 (Nov 3). Doi: 10.1245/s10434-022-12662-2

Key clinical point: Women with breast cancer (BC), especially those with low-grade malignancy, had a greater risk of developing a second primary lung cancer.

Major finding: The risk for second primary lung cancer was 1.4 (95% CI 1.25-1.55) times higher in patients with BC compared with the general population, with estrogen receptor-negative BC, low Ki67 levels, and no lymph node metastasis (all P = .01) being significant risk factors. Among patients who developed lung cancer, the rate of epidermal growth factor receptor mutation was high (78.5%).

Study details: This study analyzed the data of 9179 patients with BC, of which 6512 patients had undergone diagnostic chest computed tomography and 55 patients were diagnosed with a second primary lung cancer.

Disclosures: This study was supported by the National Key Research and Development Program of China and other sources. The authors declared no conflicts of interest.

Source: Zeng T et al. High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer. Front Oncol. 2022;12:985734 (Oct 13). Doi: 10.3389/fonc.2022.985734

Key clinical point: Women with breast cancer (BC), especially those with low-grade malignancy, had a greater risk of developing a second primary lung cancer.

Major finding: The risk for second primary lung cancer was 1.4 (95% CI 1.25-1.55) times higher in patients with BC compared with the general population, with estrogen receptor-negative BC, low Ki67 levels, and no lymph node metastasis (all P = .01) being significant risk factors. Among patients who developed lung cancer, the rate of epidermal growth factor receptor mutation was high (78.5%).

Study details: This study analyzed the data of 9179 patients with BC, of which 6512 patients had undergone diagnostic chest computed tomography and 55 patients were diagnosed with a second primary lung cancer.

Disclosures: This study was supported by the National Key Research and Development Program of China and other sources. The authors declared no conflicts of interest.

Source: Zeng T et al. High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer. Front Oncol. 2022;12:985734 (Oct 13). Doi: 10.3389/fonc.2022.985734

Key clinical point: Women with breast cancer (BC), especially those with low-grade malignancy, had a greater risk of developing a second primary lung cancer.

Major finding: The risk for second primary lung cancer was 1.4 (95% CI 1.25-1.55) times higher in patients with BC compared with the general population, with estrogen receptor-negative BC, low Ki67 levels, and no lymph node metastasis (all P = .01) being significant risk factors. Among patients who developed lung cancer, the rate of epidermal growth factor receptor mutation was high (78.5%).

Study details: This study analyzed the data of 9179 patients with BC, of which 6512 patients had undergone diagnostic chest computed tomography and 55 patients were diagnosed with a second primary lung cancer.

Disclosures: This study was supported by the National Key Research and Development Program of China and other sources. The authors declared no conflicts of interest.

Source: Zeng T et al. High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer. Front Oncol. 2022;12:985734 (Oct 13). Doi: 10.3389/fonc.2022.985734

Key clinical point: The risk of developing breast cancer (BC) was slightly elevated in women who received treatment for thyroid cancer, with increasing cumulative ¹³¹I activity being an important risk factor.

Major finding: Compared with the general population, the risk for BC was 1.5 times higher in thyroid cancer survivors (standardized incidence ratio 1.52; 95% CI 1.36-1.69). Although ¹³¹I treatment did not increase the risk for subsequent BC, the risk increased with increasing cumulative ¹³¹I activity (excess relative risk per 100 mCi 17%; 95% CI 2%-38%).

Study details: This pooled analysis included 8475 women who were treated for differentiated thyroid cancer, of which 62% received radiotherapy with ¹³¹I.

Disclosures: This study was supported by grants from the European Commission and other sources. The authors declared no conflicts of interest.

Source: Tran TVT et al. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. Br J Cancer. 2022 (Oct 12). Doi: 10.1038/s41416-022-01982-5

Key clinical point: The risk of developing breast cancer (BC) was slightly elevated in women who received treatment for thyroid cancer, with increasing cumulative ¹³¹I activity being an important risk factor.

Major finding: Compared with the general population, the risk for BC was 1.5 times higher in thyroid cancer survivors (standardized incidence ratio 1.52; 95% CI 1.36-1.69). Although ¹³¹I treatment did not increase the risk for subsequent BC, the risk increased with increasing cumulative ¹³¹I activity (excess relative risk per 100 mCi 17%; 95% CI 2%-38%).

Study details: This pooled analysis included 8475 women who were treated for differentiated thyroid cancer, of which 62% received radiotherapy with ¹³¹I.

Disclosures: This study was supported by grants from the European Commission and other sources. The authors declared no conflicts of interest.

Source: Tran TVT et al. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. Br J Cancer. 2022 (Oct 12). Doi: 10.1038/s41416-022-01982-5

Key clinical point: The risk of developing breast cancer (BC) was slightly elevated in women who received treatment for thyroid cancer, with increasing cumulative ¹³¹I activity being an important risk factor.

Major finding: Compared with the general population, the risk for BC was 1.5 times higher in thyroid cancer survivors (standardized incidence ratio 1.52; 95% CI 1.36-1.69). Although ¹³¹I treatment did not increase the risk for subsequent BC, the risk increased with increasing cumulative ¹³¹I activity (excess relative risk per 100 mCi 17%; 95% CI 2%-38%).

Study details: This pooled analysis included 8475 women who were treated for differentiated thyroid cancer, of which 62% received radiotherapy with ¹³¹I.

Disclosures: This study was supported by grants from the European Commission and other sources. The authors declared no conflicts of interest.

Source: Tran TVT et al. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. Br J Cancer. 2022 (Oct 12). Doi: 10.1038/s41416-022-01982-5

Key clinical point: Concomitant use of ribociclib and proton-pump-inhibitors (PPI) did not affect survival outcomes in a real-world population of patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC).

Major finding: Progression-free survival was similar among users vs nonusers of PPI in the overall population (hazard ratio [HR] 1.18; P = .594) and in the subgroup of patients with endocrine-sensitive (HR 1.22; 95% CI 0.63-2.39) and endocrine-resistant (HR 1.37; 95% CI 0.30-6.16) BC.

Study details: Findings are from a retrospective cohort study including 128 patients with HR+/HER2− mBC who received ribociclib+endocrine therapy with (n = 50) or without (n = 78) concomitant PPI.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Re MD et al. Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. Breast. 2022;66:157-161 (Oct 15). Doi: 10.1016/j.breast.2022.10.005

Key clinical point: Concomitant use of ribociclib and proton-pump-inhibitors (PPI) did not affect survival outcomes in a real-world population of patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC).

Major finding: Progression-free survival was similar among users vs nonusers of PPI in the overall population (hazard ratio [HR] 1.18; P = .594) and in the subgroup of patients with endocrine-sensitive (HR 1.22; 95% CI 0.63-2.39) and endocrine-resistant (HR 1.37; 95% CI 0.30-6.16) BC.

Study details: Findings are from a retrospective cohort study including 128 patients with HR+/HER2− mBC who received ribociclib+endocrine therapy with (n = 50) or without (n = 78) concomitant PPI.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Re MD et al. Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. Breast. 2022;66:157-161 (Oct 15). Doi: 10.1016/j.breast.2022.10.005

Key clinical point: Concomitant use of ribociclib and proton-pump-inhibitors (PPI) did not affect survival outcomes in a real-world population of patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC).

Major finding: Progression-free survival was similar among users vs nonusers of PPI in the overall population (hazard ratio [HR] 1.18; P = .594) and in the subgroup of patients with endocrine-sensitive (HR 1.22; 95% CI 0.63-2.39) and endocrine-resistant (HR 1.37; 95% CI 0.30-6.16) BC.

Study details: Findings are from a retrospective cohort study including 128 patients with HR+/HER2− mBC who received ribociclib+endocrine therapy with (n = 50) or without (n = 78) concomitant PPI.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Re MD et al. Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. Breast. 2022;66:157-161 (Oct 15). Doi: 10.1016/j.breast.2022.10.005

Key clinical point: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was associated with a higher incidence of chemotherapy-induced peripheral neuropathy (CIPN) than docetaxel or paclitaxel in women with invasive breast cancer (BC).

Major finding: The risk for patient-reported CIPN was lower in the paclitaxel (hazard ratio [HR] 0.59; P = .008) and docetaxel (HR 0.65; P = .02) groups compared with the nab-paclitaxel group, with lesser sensory discomfort being reported by patients receiving paclitaxel (HR 0.44) or docetaxel (HR 0.52; both P < .001) vs nab-paclitaxel.

Study details: Findings are from a prospective cohort study including 1234 patients with invasive BC who received taxane-containing chemotherapy, of which 23.9%, 41.7%, and 34.4% of patients received nab-paclitaxel, paclitaxel, and docetaxel, respectively.

Disclosures: This study was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Dr. Xu declared receiving personal fees from several sources.

Source: Mo H et al. Association of taxane type with patient-reported chemotherapy-induced peripheral neuropathy among patients with breast cancer. JAMA Netw Open. 2022;5(11):e2239788 (Nov 2). Doi: 10.1001/jamanetworkopen.2022.39788

Key clinical point: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was associated with a higher incidence of chemotherapy-induced peripheral neuropathy (CIPN) than docetaxel or paclitaxel in women with invasive breast cancer (BC).

Major finding: The risk for patient-reported CIPN was lower in the paclitaxel (hazard ratio [HR] 0.59; P = .008) and docetaxel (HR 0.65; P = .02) groups compared with the nab-paclitaxel group, with lesser sensory discomfort being reported by patients receiving paclitaxel (HR 0.44) or docetaxel (HR 0.52; both P < .001) vs nab-paclitaxel.

Study details: Findings are from a prospective cohort study including 1234 patients with invasive BC who received taxane-containing chemotherapy, of which 23.9%, 41.7%, and 34.4% of patients received nab-paclitaxel, paclitaxel, and docetaxel, respectively.

Disclosures: This study was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Dr. Xu declared receiving personal fees from several sources.

Source: Mo H et al. Association of taxane type with patient-reported chemotherapy-induced peripheral neuropathy among patients with breast cancer. JAMA Netw Open. 2022;5(11):e2239788 (Nov 2). Doi: 10.1001/jamanetworkopen.2022.39788

Key clinical point: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was associated with a higher incidence of chemotherapy-induced peripheral neuropathy (CIPN) than docetaxel or paclitaxel in women with invasive breast cancer (BC).

Major finding: The risk for patient-reported CIPN was lower in the paclitaxel (hazard ratio [HR] 0.59; P = .008) and docetaxel (HR 0.65; P = .02) groups compared with the nab-paclitaxel group, with lesser sensory discomfort being reported by patients receiving paclitaxel (HR 0.44) or docetaxel (HR 0.52; both P < .001) vs nab-paclitaxel.

Study details: Findings are from a prospective cohort study including 1234 patients with invasive BC who received taxane-containing chemotherapy, of which 23.9%, 41.7%, and 34.4% of patients received nab-paclitaxel, paclitaxel, and docetaxel, respectively.

Disclosures: This study was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Dr. Xu declared receiving personal fees from several sources.

Source: Mo H et al. Association of taxane type with patient-reported chemotherapy-induced peripheral neuropathy among patients with breast cancer. JAMA Netw Open. 2022;5(11):e2239788 (Nov 2). Doi: 10.1001/jamanetworkopen.2022.39788